RIGL FY 2025 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$294M+64.1% YoY

Gross Profit

$275M93.3% margin

Operating Income

$125M42.6% margin

Net Income

$367M124.7% margin

EPS (Diluted)

$19.48

Cash Flow

Operating Cash Flow

$76M

Free Cash Flow

$76M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$514M

Total Liabilities

$122M

Stockholders' Equity

$391M

Cash & Equivalents

$41M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$294M	$179M	+64.1%
Gross Profit	$275M	$161M	+71.0%
Operating Income	$125M	$24M	+418.6%
Net Income	$367M	$17M	+1999.1%